{"groups":[{"description":"50 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG000","title":"Cohort 1"},{"description":"100 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG001","title":"Cohort 2"},{"description":"200 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG002","title":"Cohort 3"},{"description":"400 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG003","title":"Cohort 4"},{"description":"500 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG004","title":"Cohort 5"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Escalation Phase","id":"FG005","title":"Cohort 6"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Confirmation Phase","id":"FG006","title":"Cohort A"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose Confirmation Phase","id":"FG007","title":"Cohort B"},{"description":"300 mg LY3009120 administered orally every 12 hours daily in a 28-day cycle.\n\nDose confirmation Phase","id":"FG008","title":"Cohort C"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"13"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"7"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"Withdrawal Caregiver Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"16"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"16"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"10"}],"type":"Received at Least One Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"16"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study consisted of two parts: Part A, a dose escalation phase to determine recommend Phase 2 dose. During Part A, safety data will be assessed and used as primary criteria for dose escalation. Part B, a tumor-specific expansion of treatment groups (cohorts) for dose confirmation."}